AmplideX® Nanopore Carrier Plus Kit uses nanopore
sequencing to resolve high-prevalence genes.
MINNEAPOLIS and OXFORD, England, March 3,
2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Asuragen, a Bio-Techne brand, has teamed
up with Oxford Nanopore Technologies to launch the
AmplideX® Nanopore Carrier Plus Kit, a new genetic panel
and supporting analysis software for carrier screening research.
This innovative kit helps laboratories resolve genes that are
challenging to analyze by conventional short-read sequencing and
only partially resolved by ancillary assays. The panel is available
for research use only.
In 2021, the American College of Medical Genetics and Genomics
(ACMG) updated its recommendations for carrier screening to include
many genes that cannot be analyzed by standard short-read
sequencing. In fact, half of the 10 most common genes that
contribute to the risk of couples having a child with a genetic
disorder are problematic for short-read sequencing. Until now,
laboratories have relied on multiple test technologies, including
MLPA, Sanger sequencing, qPCR, long-range PCR, and others, to
analyze the recommended genes.
The AmplideX Nanopore Carrier Plus Kit addresses two problems
for laboratories: it provides a single streamlined method, and it
delivers comprehensive sequencing data compared to alternative
assays. By combining novel AmplideX long-range PCR and nanopore
long reads, it directly captures large genomic variants. The
11-gene panel includes the most prevalent recommended genes that
cannot be detected accurately with legacy short-read sequencing
methods, allowing labs to replace a patchwork testing approach with
a single workflow to simplify sample-to-answer results. The kit
also includes software to enable straightforward analysis without
the need for advanced bioinformatics resources.
"Our Asuragen brand is known globally for its thoughtfully
designed, high-quality molecular diagnostic products,"
said Dr. Matt McManus, President of Bio-Techne's
Diagnostics & Spatial Biology Segment. "We chose nanopore
sequencing to support the AmplideX Nanopore Carrier Plus Kit
because it accurately delivers the richer data and longer reads
required, making it an ideal solution for labs looking to provide
superior and cost-effective carrier screening research
results."
Gordon Sanghera, CEO of Oxford
Nanopore Technologies, commented: "We are delighted that the
Bio-Techne team recognizes the unique value of rich nanopore reads
to support this important new gene panel for carrier screening
research. Bio-Techne has a long and well-deserved reputation for
delivering simpler and more reliable testing workflows with
gold-standard reagents and kits to generate better answers. We
expect this new panel will be a welcome relief for laboratory teams
that have until now been forced to deploy a half-dozen or more
technologies to adhere to expanded carrier screening
guidelines."
The AmplideX Nanopore Carrier Plus Kit targets the following
genes: CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1,
HBA2, HBB, SMN1, SMN2, and TNXB.
About Oxford Nanopore Technologies
Oxford Nanopore Technologies' goal is to bring the widest
benefits to society through enabling the analysis of anything, by
anyone, anywhere. The company has developed a new generation of
nanopore-based sensing technology for real-time, high-performance,
accessible, and scalable analysis of DNA and RNA. The technology is
used in more than 120 countries to understand the biology of humans
and diseases such as cancer, plants, animals, bacteria, viruses,
and whole environments. Oxford Nanopore Technologies products are
intended for molecular biology applications and are not intended
for diagnostic purposes. For more, visit:
https://nanoporetech.com/
Contact:
media@nanoporetech.com
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated approximately $1.2
billion in net sales in fiscal 2024 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit https://www.bio-techne.com or follow the
Company on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Contact:
David Clair,
Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-new-panel-resolving-hard-to-decipher-carrier-screening-genes-302389252.html
SOURCE Bio-Techne Corporation
